Phase I Clinical Trial with the AMC-Bioartificial Liver

@article{vandeKerkhove2002PhaseIC,
  title={Phase I Clinical Trial with the AMC-Bioartificial Liver},
  author={Maarten-Paul van de Kerkhove and Ernesto Di Florio and Vincenzo Scuderi and Aldo Mancini and Antonello Belli and Adele Bracco and Mario Dauri and Giuseppe Tisone and Giuseppe Di Nicuolo and Pietro Amoroso and Alessandro Spadari and Guido Lombardi and Ruurdtje Hoekstra and Fulvio Calise and Robert A. F. M. Chamuleau},
  journal={The International Journal of Artificial Organs},
  year={2002},
  volume={25},
  pages={950 - 959}
}
Recently a bio-artificial liver (BAL) system has been developed at the Academic Medical Center (AMC) of Amsterdam to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT). After successful testing of the AMC-BAL in rodents and pigs with ALF, a phase I study in ALF patients waiting for (OLT) was started in Italy. We present the safety outcome of the first 7 patients aged 21–56 years with coma grade III or IV. The total AMC-BAL treatment time ranged from 8 to 35… 
Liver Support Therapy: An Overview of the AMC-Bioartificial Liver Research
TLDR
The future of the BAL resides in the development of a human-derived hepatocyte cell line as biocomponent of BAL systems, because xenotransplantation legislation in many European countries prohibits the use of porcine hepatocytes in clinically applied BAL systems.
Issues in Bioartificial Liver Support Therapy for Acute Liver Failure
TLDR
The clinical efficacy of both AL (detoxification) and BAL (cell-based metabolic support) will be verified in the next 10 years, however, the clinical timing and indication will be different for the two systems: detoxification approaches will be employed earlier in the disease progression and, most likely, for AoCLF while BAL support will be used to support ALF patients andwill be used when the disease continues to progress despite best medical therapy and detoxification.
Bioartificial liver support systems for acute liver failure: A systematic review and meta-analysis of the clinical and preclinical literature
TLDR
BAL may reduce the mortality of ALF by bridging the gap between preclinical experiments and clinical trials, and Clinical trials using improved BAL must be designed scientifically and conducted in the future to provide evidence for transformation.
Pig Liver Xenotransplantation as a Bridge to Allotransplantation: Which Patients Might Benefit?
TLDR
If several barriers to successful pig organ xenoTx remain, for example, coagulation dysfunction between pig and primate, if these can be resolved by further genetic engineering of the organ-source pigs, a pig liver may prove life saving to patients dying rapidly of liver failure.
Bioartificial liver systems: why, what, whither?
TLDR
A novel bioreactor design is described that closely mimics the native liver cell environment and is easily scaled from microscopic (<1 ml cells) to clinical size, while maintaining the same local cell environment throughout theBioreactor.
Bioartificial liver: current status.
TLDR
An overview of artificial and bioartificial liver support devices gives a brief overview on these artificial andBioartificial devices and discusses remaining obstacles.
End-stage liver failure: filling the treatment gap at the intensive care unit
TLDR
The state-of-the-art of non-cell based and cell-based artificial liver support systems, cell transplantation and plasma exchange, with the first therapy relying on detoxification, while the others aim to correct also other failing liver functions and/or modulate the immune response.
Functional evaluation of a new bioartificial liver system in vitro and in vitro.
TLDR
The new BAL system has the ability to perform liver functions and can be used to treat ALF and in the BAL treatment group, blood ALT, TB and ammonia levels in canines decreased significantly.
Cell-based clinical and experimental methods for assisting the function of impaired livers – Present and future of liver support systems
TLDR
This review article is focused on research results that utilize living cells in order to establish bridging therapies in cases of liver failure, including both experimental and clinically tested techniques, such as hepatocyte transplantation and usage of the hybrid bioartificial liver devices.
Transport advances in disposable bioreactors for liver tissue engineering.
Acute liver failure (ALF) is a devastating diagnosis with an overall survival of approximately 60%. Liver transplantation is the therapy of choice for ALF patients but is limited by the scarce
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.
TLDR
A bioartificial liver to treat patients with severe liver failure until they can be either transplanted or recover spontaneously and the authors' clinical experience with the BAL has yielded encouraging results.
Clinical Experience with a Porcine Hepatocyte-Based Liver Support System
TLDR
A bioartificial liver based on plasma perfusion through a circuit of a hollow-fiber cartridge seeded with matrix-anchored porcine hepatocytes is developed to treat patients with severe acute liver failure and suggests that it may serve as “bridge” to OLT in patients with FHF primarily by reversing intracranial hypertension.
Treatment of Severe Liver Failure with a Bioartificial Liver a
TLDR
The clinical experience demonstrates that the BAL can serve as a bridge to OLT in patients with acute liver failure and that two patients, recovered, later were successfully transplanted and survived.
Clinical use of a bioartificial liver in the treatment of acetaminophen-induced fulminant hepatic failure.
TLDR
The BAL support system seems to improve the outcome of high-risk patients with acetaminophen-induced fulminant hepatic failure, even in the absence of liver transplantation.
ASSESSMENT OF THE AMC-BIOARTIFICIAL LIVER IN THE ANHEPATIC PIG1
TLDR
Treatment of anhepatic pigs with the AMC-BAL containing autologous hepatocytes significantly increases survival time, which is associated with a significant decrease in blood ammonia and total/direct bilirubin levels.
A Bioartificial Liver to Treat Severe Acute Liver Failure
TLDR
The bioartificial liver developed by the authors is safe and serves as an effective “bridge” to liver transplant in some patients and in vivo in experimental animals with liver failure.
Use of a novel bioartificial liver in a patient with acute liver insufficiency.
TLDR
This preliminary report of the first use of this novel BAL system in conjunction with plasmapheresis appears promising and a clinical study is now in progress to prove its efficacy.
Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation.
TLDR
The HepatAssist 2000 is well tolerated, improves cerebral function, and may be used as a bridge to transplantation for patients with liver failure.
Safety Observations in Phase I Clinical Evaluation of the Excorp Medical Bioartificial Liver Support System after the First Four Patients
TLDR
A Phase I clinical safety evaluation of the Excorp Medical, Inc, Bioartificial Liver Support System (BLSS) is in progress, and preliminary evaluation of safety considerations after enrollment of the first four patients is presented.
Pilot‐controlled trial of the extracorporeal liver assist device in acute liver failure
TLDR
Assessment of additive function for the device revealed an improvement in galactose elimination capacity after 6 hours of haemoperfusion, and better indices of prognosis will be required, in addition to those used to select for transplantation, if patients at an earlier stage of clinical deterioration are to be included in future studies.
...
1
2
3
4
5
...